Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the US, Europe and other territories outside China and Southeast Asia. Credit: CDC / Unsplash.

Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis.

Under the deal terms, Disc Medicine will have exclusive rights to develop and market MWTX-003, as well as other new anti-TMPRSS6 monoclonal antibodies, discovered by Mabwell, in Europe, the US and other territories excluding China and some other territories in Southeast Asia.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

By controlling iron homeostasis, MWTX-003 can address several hematologic disorders, such as polycythemia vera (PV) and beta-thalassemia.

It showed potent and durability in serum iron suppression and efficacy in animal models of beta-thalassemia and PV.

In November last year, the US Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for MWTX-003.

Disc Medicine intends to commence a Phase I study of MWTX-003 in healthy volunteers in the second half of the year.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Disc Medicine CEO and president John Quisel said: “Disc has built deep expertise in the role of iron homeostasis in hematologic disorders, and I am thrilled to expand our portfolio with these highly complementary antibody programmes.

“We are delighted to be partnering with Mabwell, a company with a strong antibody technology platform that is led by Dr Xin Du, a leading expert on TMPRSS6 biology.

“This programme is in perfect alignment with our strategy and we look forward to advancing MWTX-003 into Phase I studies later this year.”

As per terms of the agreement, Mabwell will receive $10m in upfront cash payment and also be eligible for up to $412.5m development and commercial milestones.

Disc Medicine stated that the deal is subject to customary closing conditions and approval from Mabwell Therapeutics’s parent company Mabwell shareholders.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now